var data={"title":"Protein C, concentrate from human plasma: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Protein C, concentrate from human plasma: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/324209?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=protein-c-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;Protein C, concentrate from human plasma: Drug information&quot;</a> and <a href=\"topic.htm?path=protein-c-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">see &quot;Protein C, concentrate from human plasma: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4594766\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ceprotin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12809651\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticoagulant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Enzyme</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923413\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patient variables (including age, clinical condition, and plasma levels of protein C) will influence dosing and duration of therapy. Individualize dosing based on protein C activity and patient's pharmacokinetic profile.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Severe congenital protein C deficiency:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Acute episode/short-term prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 100-120 units/kg/dose (for determination of recovery and half-life); followed by subsequent 3 doses: 60-80 units/kg/dose every 6 hours adjusted to maintain peak protein C activity of 100%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: 45-60 units/kg/dose every 6 or 12 hours adjusted to maintain recommended maintenance trough protein C activity levels &gt;25%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Long-term prophylaxis: Maintenance dose: 45-60 units/kg/dose every 12 hours (recommended maintenance trough protein C activity levels &gt;25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Note:</b> Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Purpura fulminans secondary to meningococcemia:</b> Limited data available. IV: A retrospective review of 94 pediatric patients (0-18 years including eight newborns) reported a median dose of 100 units/kg/day divided every 4-6 hours was used in the majority of patients (78 of the 94 patients); the other dosing in the remaining patients was an initial bolus with the remainder of daily dose administered as a continuous IV infusion (dosing specifics were not provided); median treatment duration of 33 hours (range: 1-645 hours); daily dose range: 28-375 units/kg/day (Veldman, 2010). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12809660\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=protein-c-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;Protein C, concentrate from human plasma: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patient variables (including age, clinical condition, and plasma levels of protein C) will influence dosing and duration of  therapy. Individualize dosing based on protein C activity and patient's pharmacokinetic profile.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Severe congenital protein C deficiency:</b> IV: Infants, Children, Adolescents, and Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute episode/short-term prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 100-120 units/kg/dose (for determination of recovery and half-life) followed by subsequent 3 doses: 60-80 units/kg/dose every 6 hours adjusted to maintain peak protein C activity of 100%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: 45-60 units/kg/dose every 6 or 12 hours adjusted to maintain recommended maintenance trough protein C activity levels &gt;25%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Long-term prophylaxis: Maintenance dose: 45-60 units/kg/dose every 12 hours (recommended maintenance trough protein C activity levels &gt;25%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\"> <b>Note:</b> Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Purpura fulminans secondary to meningococcemia:</b> Limited data available: Infants &gt;1month, Children, and Adolescents: IV: 100-150 units/kg/dose every 6 hours for 72 hours then 50-150 units/kg/dose every 12 hours until target symptom/sign resolution or treatment duration reaches 7 days. This protocol was used in a Phase II, double-blind, placebo-controlled, dose-finding study of 40 pediatric patients [median age: 2.3 years (range: 2.4 months-16.1 years)] (de Kleinjn, 2003). A retrospective review of 94 pediatric patients (newborn to 18 years) reported a median dose of 100 units/kg/day divided every 4-6 hours or as an initial bolus with the remainder of daily dose administered as a continuous IV infusion (dosing specifics were not provided); median treatment duration of 2 days (range: 1-24 days); daily dose range: 28-375 units/kg/day (Veldman, 2010). An open-label, prospective study of 36 patients (3 months to 76 years) reported an initial dose of 100 units/kg followed by a continuous IV infusion with an initial rate of 10 units/kg/hour adjusted daily to maintain plasma protein C concentration 80-120 units/mL (White, 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595369\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceprotin: 500 units (1 ea); 1000 units (1 ea) [contains albumin human, heparin, mouse (murine) and/or hamster protein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4594768\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12809661\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Administer by IV injection; infusion must be completed within 3 hours of solution preparation. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neonates, Infants, and Children &lt;10 kg: Rate should not exceed 0.2 mL/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;10 kg, Adolescents, and Adults: Rate should not exceed 2 mL/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595351\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Administer within 3 hours of reconstitution and discard any unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12809652\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Replacement therapy for severe congenital protein C deficiency for the prevention and/or treatment of venous thromboembolism and purpura fulminans (FDA approved in neonatal, pediatric, and adult patients). Has also been used in patients with purpura fulminans secondary to meningococcemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4594763\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceprotin may be confused with aprotinin, Cipro</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protein C concentrate (human) may be confused with activated protein C (human, recombinant) which refers to drotrecogin alfa</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595343\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all drugs which may affect hemostasis, bleeding may be associated with protein C administration. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents that alter hemostasis and patient susceptibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (pruritus and rash)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Fever, hemothorax, hypotension, hyperhidrosis, restlessness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595337\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595338\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heparin-induced thrombocytopenia (HIT): Trace amounts of heparin contained within the formulation may lead to HIT; evaluate platelet counts if HIT is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: May contain trace amounts of mouse protein and/or heparin. Discontinue use in the presence of hypersensitivity/allergic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; monitor patients closely for sodium overload.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium-restricted patients: Use with caution in patients where sodium restriction is necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease; screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces this risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299957\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595347\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16776&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595332\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595333\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproductive studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12809662\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Protein C activity (chromogenic assay) prior to and during therapy (if acute thrombotic event, check protein C activity immediately before next injection); signs and symptoms of bleeding; hemoglobin/hematocrit, PT/INR, platelet count</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12809663\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595353\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Converted to activated protein C (APC). APC is a serine protease which inactivates factors Va and VIIIa, limiting thrombotic formation. <i>In vitro </i>data also suggest inhibition of plasminogen activator inhibitor-1 (PAF-1) resulting in profibrinolytic activity, inhibition of macrophage production of tumor necrosis factor, blocking of leukocyte adhesion, and limitation of thrombin-induced inflammatory responses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4595356\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Limited data suggests that infants and very young children may have a faster clearance, lower AUC and maximum serum concentration, larger volume of distribution, and shorter half-life than older subjects. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Median: 0.074L/kg (range: 0.044 to 0.165 L/kg) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Activated protein C (APC) inactivated by plasma protease inhibitors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Median: 9.8 hours; range: 4.9 to 14.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: T<sub>max</sub>: 0.5 hours; range: 0.17 to 1.33 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923483\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Conversion  to vitamin  K antagonist therapy may cause a transient hypercoagulable state during therapy initiation due to shorter half-life of protein C than other vitamin K-dependent clotting factors. For patients requiring conversion to oral vitamin K antagonists, it is recommended to continue protein C therapy during oral anticoagulant initiation until anticoagulation stabilized. It is also advised to begin with a low dose of oral anticoagulant instead of a loading dose.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prescribers should register their patients to assist in the collection and assessment of protein C concentration deficiency, treatment, safety, and outcomes of subjects. More information may be found at the following website: http://clinicaltrials.gov/ct2/show/NCT01127529.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324135\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ceprotin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539986\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ceprotin (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IS, IT, KR, KW, LT, LU, MT, NL, PL, PT, QA, RO, RU, SA, SE, SI, SK, TR);</li>\n      <li>Octaplex (BR);</li>\n      <li>Protexel (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    de Kleijn ED, de Groot R, Hack CE, et al, &quot;Activation of Protein C Following Infusion of Protein C Concentrate in Children With Severe Meningococcal Sepsis and Purpura Fulminans: A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding Study,&quot; <i>Crit Care Med</i>, 2003, 31(6):1839-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protein-c-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/12794428/pubmed\" target=\"_blank\" id=\"12794428\">12794428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veldman A, Fischer D, Wong FY, et al, &quot;Human Protein C Concentrate in the Treatment of Purpura Fulminans: A Retrospective Analysis of Safety and Outcome in 94 Pediatric Patients,&quot; <i>Crit Care</i>, 2010, 14(4):R156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protein-c-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/20723255/pubmed\" target=\"_blank\" id=\"20723255\">20723255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White B, Livingstone W, Murphy C, et al, &quot;An Open-Label Study of the Role of Adjuvant Hemostatic Support With Protein C Replacement Therapy in Purpura Fulminans-Associated Meningococcemia,&quot; <i>Blood</i>, 2000, 96(12):3719-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/protein-c-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/11090052/pubmed\" target=\"_blank\" id=\"11090052\">11090052</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16776 Version 78.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F4594766\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F12809651\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12923413\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F12809660\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F4595369\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F4594768\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F12809661\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F4595351\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F12809652\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F4594763\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4595343\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F4595337\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F4595338\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299957\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F4595347\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F4595332\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4595333\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F12809662\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F12809663\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4595353\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F4595356\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F12923483\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324135\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539986\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16776|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=protein-c-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">Protein C, concentrate from human plasma: Drug information</a></li><li><a href=\"topic.htm?path=protein-c-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">Protein C, concentrate from human plasma: Patient drug information</a></li></ul></div></div>","javascript":null}